

Pre-Congress Symposia: Oct 4-6 & 11-13, 2021 Main Congress: Oct 20-23, 2021

— eanm21.eanm.org ——

34th Annual Congress of the European Association of Nuclear Medicine

Joint Symposium 16

Oncology & Theranostics Committee / European Society for Medical Oncology (ESMO) Accessible on-demand at any time

Session Title

Combination Treatments - What can Radioligand Therapy be Combined with?

Chairperson

Ken Herrmann (Essen, Germany)

Programme

- 29 min Ursula Vogl (Bellinzona, Switzerland / ESMO): Combination Treatment in Prostate Cancer
- 29 min Marianne Pavel (Erlangen, Germany): Combination Treatment in NETs
- 29 min Johannes Czernin (Los Angeles, United States of America): Preclinical Considerations for Combination Treatment
- 3 min Session Summary by Chairperson

Educational Objectives

- 1. Understanding the potential upside of combination therapy including RLT
- 2. Discussion of early experiences in combining RLT with other therapies in NETs and prostate cancer
- 3. Learning preclinical concepts of investigating combination treatment involving RLT

Summary

Radioligand therapy (RLT) is one of the most exciting developments in nuclear medicine. Despite the intriguing results of NETTER-1 and the positive VISION study a significant proportion lot of patients do not or only temporarily benefit from RLT. The rationale of combination treatment, an established concept in oncology, seems to be the consistent next step in establishing RLT in clinical care. This session is dedicated to explore if and how RLT can be combined with in regards to prostate cancer and NETs. Moreover, there will be a dedicated talk to learn also about preclinical considerations for combination treatment.

Key Words

RLT - combination therapy - NETs - prostate cancer



Pre-Congress Symposia: Oct 4-6 & 11-13, 2021 Main Congress: Oct 20-23, 2021

— eanm21.eanm.org ——

34th Annual Congress of the European Association of Nuclear Medicine

Joint Symposium 24

Thyroid + Oncology & Theranostics Committee / European Society for Medical Oncology (ESMO) Accessible on-demand at any time

Session Title

Theranostics in Thyroid Cancer Beyond Radioactive Iodine

Chairperson

Désirée Deandreis (Turin, Italy)

Programme

- 25 min Sophie Leboulleux (Villejuif, France / ESMO): Molecular Basis of Differentiated Thyroid Cancer
- 20 min Calogero D'Alessandria (Munich, Germany): New Targets for Thyroid Cancer in Pre-Clinical Research
- 20 min Martina Sollini (Milan, Italy): PSMA in Thyroid Cancer
- 22 min Désirée Deandreis (Turin, Italy): PRRT and Alpha Emitters in Thyroid Cancer
- 3 min Session Summary by Chairperson

Educational Objectives

- 1. Molecular basis of differentiated thyroid cancer
- 2. Insights in the identification and development of new radiopharmaceuticals in pre-clinical research
- 3. Evidence and Perspectives in the use of radiopharmaceuticals others than radioactive iodine for radiometabolic treatment in thyroid cancer including Peptide Receptor Radionuclides Therapy, alpha emitters and PSMA.

Summary

The standard treatment of differentiated thyroid cancer is radioactive iodine (RAI) but almost half of the metastatic patients become refractory to RAI. New insights in the molecular pathways involved in thyroid cancer and the research of new targets for radionuclide therapy are needed. The awareness on the perspectives both in pre-clinical and in clinical research of alternative radionuclide therapy as well the development of new radiopharmaceuticals with theragnostic purpose are mandatory.

Key Words

Differentiated thyroid cancer, molecular basis, new targets, theragnostic